María Buti Ferret-rekin lankidetzan egindako argitalpenak (6)

2016

  1. Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 8, pp. 923-926

2015

  1. Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis

    Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 2, pp. 1282-1291

  2. ITPA genotypes predict anemia but do not affect virological response with interferon-free faldaprevir, deleobuvir, and ribavirin for HCV infection

    PLoS ONE, Vol. 10, Núm. 12

  3. Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study

    Liver International, Vol. 35, Núm. 2, pp. 417-421

2013

  1. Faldaprevir and deleobuvir for HCV genotype 1 infection

    New England Journal of Medicine, Vol. 369, Núm. 7, pp. 630-639

2011

  1. The state of hepatitis B and C in Europe: Report from the hepatitis B and C summit conference

    Journal of Viral Hepatitis, Vol. 18, Núm. SUPPL. 1, pp. 1-16